Additional sex combs-like 3 divergent transcript (ASXL3-DT)

The term "ASXL3 divergent transcript" (ASXL3-DT) most likely refers to a non-coding, alternatively spliced, or divergent RNA transcript from the **ASXL3 locus**. The canonical and functionally established gene product of ASXL3 is **Additional sex combs-like 3**, a chromatin remodeling protein implicated in developmental disorders such as Bainbridge–Ropers syndrome and thought to be a predicted cancer-associated gene[1][2][3]. There is no established evidence that "ASXL3 divergent transcript" (ASXL3-DT) refers to a canonical therapeutic target, receptor, enzyme, transporter, or other protein of pharmacological interest. The literature focuses on the protein-coding gene ASXL3 and its role as an **epigenetic regulator and scaffolding protein** for chromatin remodeling complexes[1][2][3]. There is no published evidence supporting the biological or disease relevance of "ASXL3-DT" as a distinct therapeutic target, and it may be incorrectly specified or lack sufficient molecular characterization to serve as a drug discovery target. Therefore, this entity should be treated with caution; it is best regarded as a non-canonical, non-target annotation until proven otherwise. The only established canonical entity at this locus is the **ASXL3 protein**.

Other names

ASXL3 divergent transcriptASXL3-DTASXL3 (gene symbol for main protein-coding gene)